Selected article for: "intervention time and time duration"

Author: Andrews, Denise; Chetty, Yumela; Cooper, Ben S.; Virk, Manjinder; Glass, Stephen K; Letters, Andrew; Kelly, Philip A.; Sudhanva, Malur; Jeyaratnam, Dakshika
Title: Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use
  • Document date: 2017_10_10
  • ID: 1sdt9zz8_18
    Snippet: The primary outcome studied was the length of hospital stay defined as the time between hospital admission and hospital discharge. The FilmArray® RP panel is relatively expensive (£89-£133 for the consumables and £28, 000-£33,000 for the capital purchase of the system depending upon the country) compared to currently employed routine tests, (£50 per test for our standard laboratory method). However the average cost for managing pneumonia in.....
    Document: The primary outcome studied was the length of hospital stay defined as the time between hospital admission and hospital discharge. The FilmArray® RP panel is relatively expensive (£89-£133 for the consumables and £28, 000-£33,000 for the capital purchase of the system depending upon the country) compared to currently employed routine tests, (£50 per test for our standard laboratory method). However the average cost for managing pneumonia in the community is estimated at £100 per episode compared with £1700-5100 for hospitalised patients in the UK [14] and $8000 in the US [15] . Thus if a FilmArray® POC result allows earlier discharge, the consequent financial savings from the shorter hospital stay may offset the extra test costs and prove cost-beneficial, hence our choice of primary outcome. The secondary outcomes were antimicrobial prescription/s (antibiotics: any versus none, duration, time to prescription within the first 72 h of the patient's stay and prescribing decisions within 24 h after the the diagnostic results under investigation: start, stop, de-escalation, escalation and continued use, as assessed by the Chief Investigator), readmission rates and all-cause mortality (both within 30 days of the test) and length of studyward stay (i.e. removing the length of stay on subsequent wards to which the patient was transferred, where relevant). Escalation was defined as the addition of an antibiotic/s to the existing antibiotic therapy or the substitution of the current agent with a broader agent. De-escalation was the cessation of ≥1 antibiotic when >1 antibiotic was prescribed or the substitution with a narrower agent. We collected these data prospectively and retrospectively from the electronic patient record (EPR) and the electronic patient medicines administration system (EPMA). In some cases, enrolment of the patient into the hospital administrative system occurred after examination and initiation of antibiotic therapy by the physician on the ward or in the ED. Therefore, a negative time to antibiotic administration on the ward was corrected to zero hours to antibiotics. We defined the turn-around time (TAT) of the tests as the time between hospital admission and the time of the result on the Fil-mArray® system (intervention) or the time of the result on the EPR (control).

    Search related documents:
    Co phrase search for related documents
    • administration system and average cost: 1
    • administration system and cause mortality: 1
    • antibiotic administration and broad agent: 1
    • antibiotic administration and cause mortality: 1, 2, 3
    • antibiotic therapy and broad agent: 1
    • antibiotic therapy and cause mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • antibiotic therapy and community pneumonia manage: 1
    • average cost and cause mortality: 1, 2
    • cause mortality and community pneumonia manage: 1